NLRP3 and lymphoma: Hasegawa et al. provide the first report showing that histone deacetylase inhibitors (HDACis) are responsible for NLRP3 inflammasome-mediated cell death in adult T-cell leukemia/lymphoma (ATL) cell lines and primary cells from patients.